Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in
nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM